Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Dimerix Limited ( (AU:DXB) ) is now available.
Dimerix Limited has announced the quotation of 1,692,019 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code DXB. This move, resulting from the exercise of options or conversion of other securities, is expected to enhance the company’s financial flexibility and potentially strengthen its market position by increasing its capital base.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
More about Dimerix Limited
Dimerix Limited operates in the biotechnology industry, focusing on developing innovative therapies for unmet medical needs. The company is primarily engaged in the research and development of pharmaceutical products, with a market focus on advancing treatment options for various diseases.
Average Trading Volume: 3,228,497
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$335.5M
Find detailed analytics on DXB stock on TipRanks’ Stock Analysis page.